If you are taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether these symptoms signal gastroparesis. Decades of pharmacovigilance have documented gastrointestinal side effects from GLP-1 agonists, yet distinguishing reported symptoms from a confirmed diagnosis remains a clinical challenge. This page reviews published reports and prescribing information to clarify when symptoms may appear and how they are evaluated.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation can vary from mild discomfort to severe malnutrition and hospitalization. Diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking Ozempic to gastroparesis are rooted in its pharmacology as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and activation slows gastric emptying and intestinal motility. This effect is intended to reduce postprandial glucose excursions but can become pathological, leading to gastroparesis-like symptoms.
While the Ozempic label does not explicitly list gastroparesis as a separate adverse reaction, it does report gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the drug's known effect on gastric motility supports a plausible biological link. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a key consideration. The label's warnings and cautions section addresses serious hypersensitivity reactions such as anaphylaxis and angioedema, which have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis as a potential adverse effect. The label does note that gastrointestinal adverse reactions are common and can lead to discontinuation, but it does not explicitly warn of the risk of developing gastroparesis, which is a distinct clinical entity. This gap in labeling may be relevant for patients who develop severe or persistent symptoms suggestive of gastroparesis after starting Ozempic.
Settlement-related considerations for affected patients involve several factors. First, the timeline between exposure to Ozempic and documented harm is critical. Clinical trial data show that gastrointestinal adverse reactions often occur during dose escalation, but the development of gastroparesis may be delayed or cumulative. Patients who experience symptoms after months or years of use may have a stronger temporal association. Second, the severity of harm matters: patients with confirmed gastroparesis requiring medical intervention, hospitalization, or long-term management may have stronger claims. Third, the adequacy of informed consent and prescriber communication about gastrointestinal risks could be scrutinized. If patients were not warned about the possibility of gastroparesis, they may argue that they could not make an informed decision about treatment. For patients considering legal action, documentation is essential. This includes medical records showing a diagnosis of gastroparesis, evidence of Ozempic use, and a timeline linking the two. The absence of a specific warning on the label may support arguments that the manufacturer failed to adequately communicate known risks. However, the label does disclose that gastrointestinal adverse reactions are common and can be severe enough to cause discontinuation, which may be used to argue that general warnings were provided. In summary, the evidence from clinical trials demonstrates a clear association between Ozempic and gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The pharmacological mechanism of delayed gastric emptying provides a plausible pathway. The label's warnings are general rather than specific to gastroparesis, which may be a point of contention in settlement discussions. Patients with documented harm and a clear temporal relationship to Ozempic use may have grounds for claims, but each case will depend on individual medical and legal circumstances.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, and bloating. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Key criteria include documented Ozempic use, a confirmed diagnosis of gastroparesis via gastric emptying scintigraphy or breath tests, a temporal relationship between use and symptom onset, and evidence of harm such as hospitalization or long-term management. The adequacy of warnings on the label may also be considered.
The label does not explicitly list gastroparesis as a separate adverse reaction, but it reports gastrointestinal adverse reactions like dyspepsia and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). There is no specific warning about gastroparesis, which may be relevant for legal claims.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.